Alogliptin

Из Википедије, слободне енциклопедије
Alogliptin
Alogliptin.svg
Klinički podaci
Drugs.com Monografija
Način primene Oralno
Farmakokinetički podaci
Poluvreme eliminacije 21 h
Izlučivanje Renalno (76%), fekalno (13%)
Identifikatori
CAS broj 850649-61-5 ДаY
ATC kod A10BH04 (WHO)
PubChem CID 11450633
DrugBank DB06203 ДаY
ChemSpider 9625485 ДаY
ChEBI CHEBI:72323 ДаY
ChEMBL CHEMBL376359 ДаY
Hemijski podaci
Formula C18H21N5O2
Molarna masa 339,392

Alogliptin je organsko jedinjenje, koje sadrži 18 atoma ugljenika i ima molekulsku masu od 339,392 Da.[1][2][3][4][5]

Osobine[уреди]

Osobina Vrednost
Broj akceptora vodonika 5
Broj donora vodonika 1
Broj rotacionih veza 3
Particioni koeficijent[6] (ALogP) 1,3
Rastvorljivost[7] (logS, log(mol/L)) -2,4
Polarna površina[8] (PSA, Å2) 93,7

Reference[уреди]

  1. Christopher R, Covington P, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A: Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther. 2008 Mar;30(3):513-27. PMID 18405789
  2. Covington P, Christopher R, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A: Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A random ized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther. 2008 Mar;30(3):499-512. PMID 18405788
  3. Golightly LK, Drayna CC, McDermott MT: Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012 Aug 1;51(8):501-14. doi: 10.2165/11632930-000000000-00000. PMID 22686547
  4. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. doi:10.1093/nar/gkq1126. PMC 3013709слободно за читање. PMID 21059682. 
  5. David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. doi:10.1093/nar/gkm958. PMC 2238889слободно за читање. PMID 18048412. 
  6. Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o. 
  7. Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. doi:10.1021/ci000392t. PMID 11749573. 
  8. Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. doi:10.1021/jm000942e. PMID 11020286. 

Literatura[уреди]

Spoljašnje veze[уреди]

Star of life.svg     Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).